Imunoterapia: acesso aberto
Acesso livre

Abstrato

Risk of Musculoskeletal Complications in Cancer Patients Treated with Nivolumab

Xiangyi Kong, Xiaobo Zhang and Yanguo Kong

Object: We performed a meta-analysis of the risk of selected musculoskeletal toxicities associated with the PD-1 inhibitor Nivolumab versus other drugs.

Methods: Several databases were searched. We assess the relevant articles and relative risks (RRs) with 95% confidence intervals (95% CIs) were estimated regarding the risk of arthralgia, asthenia, myalgia and extremity pain and Nivolumab versus control. Heterogeneity, sensitivity analysis and publication bias of the included studies were also analyzed.

Results: There were 5 eligible studies, including 2220 patients that were considered in the present metaanalysis. The RRs of arthralgia, asthenia, myalgia and extremity pain were 1.116 (95% CI: 0.669, 1.860; p=0.675), 0.846 (95% CI: 0.657, 1.090; p=0.197), 0.658 (95% CI: 0.141, 3.062; p=0.593), 1.037 (95% CI: 0.647, 1.662; p=0.882), respectively.

Conclusion: Our results suggested that PD-1 inhibitor Nivolumab was not associated with an increased risk of musculoskeletal toxicities including arthralgia, asthenia, and myalgia and extremity pain compared with control.